Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.02 0.43 −5.77%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
685.40 1,039.40 1,266.50 1,210.80 1,507.10 688.60 280.87 187.83 39.17 35.56
Receivables
6.40 13.70 7.20 8.00 25.70 8.40 6.28 5.03 26.04 1.41
Total current assets
700.70 1,067.30 1,280.20 1,240.20 1,552.50 703.10 290.88 195.68 65.53 37.28
Property, Plant, Equpment (Net)
5.20 7.00 11.50 13.40 12.70 12.30 8.46 3.58 1.30 0.63
Long-term assets (Other)
3.80 8.10 10.40 10.80 12.50 0.00 0.03 0.02 0.02 0.02
Total non-current assets
17.20 24.10 24.40 28.60 29.10 14.30 10.76 3.60 1.32 0.65
Total Assets
717.90 1,091.40 1,304.60 1,268.80 1,581.60 717.40 301.64 199.28 66.85 37.94
Accounts Payable
69.50 71.80 92.20 74.70 54.40 7.10 4.56 2.76 0.60 1.57
Accrued Expenses
— — — — 23.10 18.90 7.60 4.00 3.55 1.65
Current Part of Debt
— — — — — — — 0.15 0.16 0.14
Current Revenue (Deferred)
71.30 156.20 163.00 218.60 206.20 22.20 19.98 16.07 13.55 6.68
Total current liabilities
142.50 229.80 257.10 295.10 261.70 49.20 32.81 22.98 17.85 10.03
Long Term Debt (Total)
0.40 0.60 0.80 1.00 1.00 2.00 2.00 2.00 0.15 0.31
Non-current Revenue (Deferred)
134.30 292.00 386.20 405.10 534.30 22.90 38.43 37.48 48.55 3.50
Liabilities (Preferred Stock)
— — — — — — — — 0.05 0.06
Non-current Liabilities (Other)
— — — — — — — 0.15 0.00 0.06
Total non-current liabilities
141.50 299.90 387.50 408.80 538.20 26.00 42.14 39.63 48.75 3.87
Total liabilities
284.00 529.70 644.60 703.90 799.90 75.20 74.96 62.61 66.60 13.91
Additional Paid In Capital
2,136.90 2,092.20 1,995.70 1,549.40 1,469.20 1,133.50 599.10 439.12 0.00 —
Preferred Stock (Total)
— — — — — — — — 61.48 56.91
Common Stock (Net)
0.10 0.10 0.10 0.10 — 0.00 0.04 0.03 0.01 0.01
Retained Earnings
(1,612.40) (1,531.60) (1,332.70) (965.40) (682.90) (491.90) (372.56) (302.26) (62.42) (33.80)
Treasury Stock
91.90 — — — — — — — — —
Shareholders Equity (Other)
— — — — — — — — 1.19 0.94
Common Equity (Total)
433.90 561.70 660.00 564.90 781.70 642.20 226.69 136.67 (61.23) (32.88)
Shareholders Equity (Total)
433.90 561.70 660.00 564.90 781.70 642.20 226.69 136.67 0.25 24.03
Shareholders Equity and Liabilities (Total)
717.90 1,091.40 1,304.60 1,268.80 1,581.60 717.40 301.64 199.28 66.85 37.94
Shares (Common)
63.50 68.80 68.00 53.20 53.00 48.50 38.46 31.24 1.90 1.90
Shares (Preferred)
— — — — — — — — 47.44 47.44
Shareholders Equity (Tangible)
433.90 561.70 660.00 564.90 781.70 642.20 226.69 136.67 0.25 24.03
Net Debt
(685.00) (1,038.80) (1,265.70) (1,209.80) (1,506.10) (686.60) (278.87) (185.67) (38.86) (35.10)
Total Debt
0.40 0.60 0.80 1.00 1.00 2.00 2.00 2.15 0.31 0.45

Fold the line items

In millions of $ except per-share values · columns are period end dates